Intralytix, Inc.'s ShigActive™ bacteriophage therapy targeting Shigella has completed Phase 1 and Phase2a clinical trials at the Center for Vaccine Development at the University of Maryland, Baltimore School of Medicine in Baltimore, MD. The trials are registered under clinicaltrials.gov NCT05182749.

The Phase 1 safety trial showed that ShigActive™ was safe and well tolerated in healthy subjects. The results are published here: Chen WH, Woolston J, Grant-Beurmann S, Robinson CK, Bansal G, Nkeze J, Permala-Booth J, Fraser CM, Tennant SM, Shriver MC, Pasetti MF, Liang Y, Kotloff KL, Sulakvelidze A, Schwartz JA. Safety and Tolerability of ShigActive™, a Shigella spp. Targeting Bacteriophage Preparation, in a Phase 1 Randomized, Double-Blind, Controlled Clinical Trial. Antibiotics (Basel). 2024 Sep 7;13(9):858. doi: 10.3390/antibiotics13090858. PMID: 39335031; PMCID: PMC11429168. https://www.mdpi.com/2079-6382/13/9/858.